Compare SNFCA & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNFCA | TARA |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1M | 268.5M |
| IPO Year | N/A | N/A |
| Metric | SNFCA | TARA |
|---|---|---|
| Price | $8.84 | $6.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 28.5K | ★ 983.9K |
| Earning Date | 11-13-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $340,876,482.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | ★ 3.25 | N/A |
| 52 Week Low | $7.32 | $2.77 |
| 52 Week High | $12.83 | $7.82 |
| Indicator | SNFCA | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 61.00 |
| Support Level | $8.67 | $4.72 |
| Resistance Level | $9.28 | $5.14 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 54.44 | 95.55 |
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).